| (Values in U.S. Thousands) | Sep, 2025 | Jun, 2025 | Mar, 2025 | Dec, 2024 | Sep, 2024 |
| Sales | 36,320 | 40,210 | 32,000 | 14,360 | 18,880 |
| Sales Growth | -9.67% | +25.66% | +122.84% | -23.94% | +0.43% |
| Net Income | 13,700 | -5,880 | 17,000 | -10,890 | -11,040 |
| Net Income Growth | +332.99% | -134.59% | +256.11% | +1.36% | -1,880.64% |
Elite Pharma Inc
(ELTP)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Elite Pharmaceuticals, Inc. primarily engages in researching, developing, licensing, manufacturing, and marketing proprietary drug delivery systems and products. Their drug delivery technology involves releasing a drug into the bloodstream or delivering it to a target site in the body over an extended period of time or at predetermined times.
Fiscal Year End Date: 03/31